Under construction – not a live service
Sign in
Taking people in ChinaNo phase

Long-term rehabilitation training for people with pulmonary arterial hypertension

Tests long-term rehabilitation training in adults with pulmonary arterial hypertension.

Plain-language title generated from the registry record
Registry title: Continuous Effect Of Rehabilitation Training On Pulmonary Arterial Hypertension Patients

Key facts

Where
Shanghai, ChinaSee the site

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Source: NCT07149935, who can take part

Where in China

  • RenJi HospitalShanghai, ChinaTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
RenJi Hospital
Trial code
NCT07149935
Record updated
2 September 2025
Original description
This multicenter, open label, double-arm study aims at investigating the the continuous effect of long-Term rehabilitation training on clinical improvement(ITTCI) and cardiopulmonary function in pulmonary arterial hypertension patientsRead full original descriptionShow less

Continuous Effect Of Long-Term Rehabilitation Training On Clinical Improvement(TTCI) And Cardiopulmonary Function In Pulmonary Arterial Hypertension Patients- A Multicenter-randomisation Study

This multicenter, open label, double-arm study aims at investigating the the continuous effect of long-Term rehabilitation training on clinical improvement(ITTCI) and cardiopulmonary function in pulmonary arterial hypertension patients

Inclusion: Patients who suffered from pre-capillary PAH (mPAP ≥ 20 mmHg, PVR > 2 Woods unit, PAWP ≤ 15 mmHg) confirmed by right heart catheterisation; Patients who are in the status of WHO-FC I-III; Patients between 18 and 75 years old; Female subjects are not pregnant; Patients are treated with PAH-targeted drugs and are in a stable state and there is no progress of disease); Patients have not received exercise rehabilitation training within six months.

Exclusion: Patients with the following diseases or symptoms:; Pulmonary vascular occlusive disease; Respiratory diseases; Ischaemic heart disease, complex congenital heart disease (e.g., tetralogy of Fallot, etc.), cardiomyopathy, valvular disease; Active liver disease; Severe kidney disease; Motor disorders (e.g. lower limb fracture, ataxia, etc.); Malignant tumour diseases; History of syncope within 3 months; History of supraventricular or ventricular arrhythmia at rest within 3 months; Physical disability; Hb ≤ 80g / L; Systolic blood pressure ≤85mmHg.

ClinicalTrials.gov NCT07149935